Hypoxic factors are targeted in cancer therapy to use hypoxia-mediated cell death to kill cancerous cells; therefore, it is important to take into consideration that while pro-angiogenic factors, such as VEGF will be down-regulated, this treatment may either up- or down-regulate IL-1α, depending on the cell type. The gene discussed is VEGFA; the disease is cancer.